Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
暂无分享,去创建一个
R. Scheuermann | S. Mallal | A. Sette | Yun Zhang | L. Premkumar | D. Weiskopf | A. Grifoni | J. Dan | A. Frazier | G. Filaci | Nils Methot | E. Phillips | A. Tarke | T. M. Narowski
[1] James J. Davis,et al. Introducing the Bacterial and Viral Bioinformatics Resource Center (BV-BRC): a resource combining PATRIC, IRD and ViPR , 2022, Nucleic Acids Res..
[2] A. Sette,et al. Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic , 2022, Cell host & microbe.
[3] A. West,et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models , 2022, Science.
[4] A. Sette,et al. Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors , 2022, International journal of molecular sciences.
[5] P. Bjorkman,et al. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes , 2022, bioRxiv.
[6] A. Sette,et al. Inducing broad-based immunity against viruses with pandemic potential. , 2022, Immunity.
[7] A. Sette,et al. Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[8] S. Gehring,et al. Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2 , 2022, Frontiers in Immunology.
[9] M. Killerby,et al. Seasonality of Common Human Coronaviruses, United States, 2014–2021 , 2022, medRxiv.
[10] A. Sette,et al. Immunological memory to Common Cold Coronaviruses assessed longitudinally over a three-year period , 2022, bioRxiv.
[11] M. Koopmans,et al. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients , 2022, Science Immunology.
[12] A. Sette,et al. Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status , 2022, Cell Host & Microbe.
[13] A. Sette,et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant , 2022, Nature Medicine.
[14] J. Derisi,et al. Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function , 2022, JCI insight.
[15] S. Mallal,et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron , 2022, Cell.
[16] F. Noorbakhsh,et al. SARS-CoV-2 spike protein displays sequence similarities with paramyxovirus surface proteins; a bioinformatics study , 2021, PloS one.
[17] J. Sidney,et al. A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates. , 2021, Vaccine.
[18] P. Gimotty,et al. SARS-CoV-2-specific T cells in unexposed adults display broad trafficking potential and cross-react with commensal antigens , 2021, bioRxiv.
[19] F. Krammer,et al. Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination , 2021, Nature Communications.
[20] A. Sette,et al. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine , 2021, Frontiers in Immunology.
[21] A. Sette,et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells , 2021, Science.
[22] S. Richardson,et al. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner , 2021, Cell Host & Microbe.
[23] R. Scheuermann,et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.
[24] F. Balloux,et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection , 2021, medRxiv.
[25] E. Wherry,et al. Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.
[26] A. Wald,et al. Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals , 2021, PLoS pathogens.
[27] H. Schuitemaker,et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.
[28] Julia Niessl,et al. T cell immunity to SARS-CoV-2 , 2021, Seminars in Immunology.
[29] M. Koopmans,et al. SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients , 2021, Science Immunology.
[30] Bjoern Peters,et al. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19 , 2021, Cell Host & Microbe.
[31] S. Prakash,et al. Genome-Wide B Cell, CD4+, and CD8+ T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines , 2021, The Journal of Immunology.
[32] C. Szeto,et al. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses , 2021, Immunity.
[33] Shibin Zhou,et al. Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and endemic coronaviruses. , 2021, The Journal of clinical investigation.
[34] K. Schnatbaum,et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination , 2021, Science.
[35] A. Sette,et al. Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers , 2021, The Journal of infectious diseases.
[36] A. Sette,et al. Pre-existing T Cell Memory against Zika Virus , 2021, Journal of Virology.
[37] S. Mallal,et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2021, Cell Reports Medicine.
[38] Gavin J. D. Smith,et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.
[39] A. Sette,et al. Adaptive immunity to SARS-CoV-2 and COVID-19 , 2021, Cell.
[40] Leo Swadling,et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection , 2020, Science Immunology.
[41] S. Mallal,et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2020, bioRxiv.
[42] C. Dutertre,et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection , 2020, bioRxiv.
[43] P. Rosenstiel,et al. Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19 , 2020, Immunity.
[44] M. Lipsitch,et al. Cross-reactive memory T cells and herd immunity to SARS-CoV-2 , 2020, Nature Reviews Immunology.
[45] Zhènglì Shí,et al. Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.
[46] H. Rammensee,et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.
[47] N. Miller,et al. Recent endemic coronavirus infection is associated with less severe COVID-19. , 2020, The Journal of clinical investigation.
[48] Lisa E. Gralinski,et al. Animal models for COVID-19 , 2020, Nature.
[49] J. Greenbaum,et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.
[50] H. Goossens,et al. Seasonal coronavirus protective immunity is short-lasting , 2020, Nature Medicine.
[51] P. Doherty,et al. Suboptimal SARS-CoV-2−specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype , 2020, Proceedings of the National Academy of Sciences.
[52] S. Mallal,et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.
[53] Bjoern Peters,et al. Epitope prediction and identification- adaptive T cell responses in humans. , 2020, Seminars in immunology.
[54] U. Reimer,et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.
[55] S. Mallal,et al. Identification and Characterization of CD4+ T Cell Epitopes after Shingrix Vaccination , 2020, Journal of Virology.
[56] Martin Linster,et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.
[57] S. Perlman,et al. Lessons for COVID-19 Immunity from Other Coronavirus Infections , 2020, Immunity.
[58] A. Sette,et al. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns , 2020, Nature Reviews Immunology.
[59] Morten Nielsen,et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.
[60] A. Sette,et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.
[61] A. Sette,et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.
[62] T. Schumacher,et al. Profound CD8 T cell responses towards the SARS-CoV-2 ORF1ab in COVID-19 patients , 2020 .
[63] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[64] L. Ferreira,et al. CD4+ T Cells Cross-Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection , 2020, Cell reports.
[65] M. Chiarini,et al. Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[66] Sandeep Kumar Dhanda,et al. Development and Validation of a Bordetella pertussis Whole-Genome Screening Strategy , 2020, Journal of immunology research.
[67] R. Scheuermann,et al. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.
[68] A. M. Leontovich,et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.
[69] Sandeep Kumar Dhanda,et al. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species , 2020, Journal of Virology.
[70] Alessandro Sette,et al. The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..
[71] M. Diamond,et al. Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy , 2018, Nature Communications.
[72] M. Diamond,et al. Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy , 2018, Nature Communications.
[73] Anne M Johnson,et al. Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. , 2015, American journal of respiratory and critical care medicine.
[74] J. Sidney,et al. Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes , 2013, PLoS neglected tropical diseases.
[75] Jonathan J Deeks,et al. Cellular immune correlates of protection against symptomatic pandemic influenza , 2013, Nature Medicine.
[76] J. Oxford,et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans , 2012, Nature Medicine.
[77] J. Sidney,et al. Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. , 2010, Human immunology.
[78] John Sidney,et al. Immunomic Analysis of the Repertoire of T-Cell Specificities for Influenza A Virus in Humans , 2008, Journal of Virology.
[79] P. Masters,et al. The Molecular Biology of Coronaviruses , 2006, Advances in Virus Research.
[80] John Sidney,et al. Predicting population coverage of T-cell epitope-based diagnostics and vaccines , 2006, BMC Bioinformatics.
[81] John Sidney,et al. Identification and Antigenicity of Broadly Cross-Reactive and Conserved Human Immunodeficiency Virus Type 1-Derived Helper T-Lymphocyte Epitopes , 2001, Journal of Virology.
[82] John Sidney,et al. HLA-DR-Promiscuous T Cell Epitopes from Plasmodium falciparum Pre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles1 2 , 2000, The Journal of Immunology.
[83] W. R. Dowdle,et al. Coronaviridae , 1990, Virus Infections of Ruminants.
[84] M. Oudshoorn,et al. Minimal phenotype panels. A method for achieving maximum population coverage with a minimum of HLA antigens. , 1996, Human immunology.